Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis

Jing-wen Yang,Ying Zou,Jun Chen,Chen Cui,Jia Song,Meng-meng Yang,Jing Gao,Hui-qing Hu,Long-qing Xia,Li-ming Wang,Xiao-yu Lv,Li Chen,Xin-guo Hou
DOI: https://doi.org/10.1186/s12967-023-04790-4
IF: 8.44
2023-12-20
Journal of Translational Medicine
Abstract:Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most prevalent metabolic syndromes worldwide. However, no approved pharmacological treatments are available for MAFLD. Chenpi, one kind of dried peel of citrus fruits, has traditionally been utilized as a medicinal herb for liver diseases. Didymin is a newly identified oral bioactive dietary flavonoid glycoside derived from Chenpi. In this study, we investigated the therapeutic potential of Didymin as an anti-MAFLD drug and elucidated its underlying mechanisms.
medicine, research & experimental
What problem does this paper attempt to address?